| Detailed information |
|---|
| CancerLivER ID | 2225 |
| Biomarker | AFP, DCP, ( DCP with a cut-off value of 86 mAU/mL and AFP with a cut-off value of 21 ng/mL) |
| Biomarker Name/Symbol (given in Publication) | Combination of AFP and DCP ( DCP with a cut-off value of 86 mAU/mL and AFP with a cut-off value of 21 ng/mL) |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Biomarker for diagnosis of HCC and validated on independent dataset |
| Experimental Condition | HCC v/s Normal |
| Cancer type | Hepatocellular carcinoma |
| Regulation | AFP and DCP upregulated in HCC |
| Level of significance | p < 0.001 |
| Source | Serum |
| PMID | 25382443 |
| Type of Biomarker | Diagnostic |
| Pathway | NA |
| Cohort | 1,153 cases (876 male and 277 female), 550 cases in HCC group, 164 in Malignant disease group, 182 in Benign disease group, 85 in Chronic liver disease group, and 173 in Normal group |
| Sensitivity | 82.90% |
| Specificity | 90.80% |
| Accuracy | NA |
| AUC | 0.89 |
| Disease | Human Hepatitis B virus associated HCC |
| Year of Publication | 2014 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT03645655,NCT01360255,NCT01277653,NCT03047603,NCT00154531 |